Organogenesis Holdings Inc.ORGO

Organogenesis Holdings Inc. reported a net loss of $53.2 million in the quarter to 31 March 2026 on revenue of $37.2 million, delivering a $68.9 million operating loss and a negative $21.1 million of operating cash flow. Diluted earnings per share clocked in at minus $0.44 on a diluted share count of 127.8 million, while the balance sheet still showed $91.4 million in cash and $520 million in assets against $138.6 million of liabilities. Inventories rose by $8.7 million to $28.4 million, and capital spending on property, plant and equipment was $3.1 million.

Organogenesis markets regenerative tissue products across advanced wound care, sports medicine and surgery under brands such as OCMP, FiberOS and PuraForce, promising “scientific advancement” and “clinical research” on polished product pages. Yet the 10-Q quietly notes that overseas sales accounted for less than 1% of total product revenue in the periods presented, and the company’s 2023 licence deal with Vivex Biologics for CYGNUS Dual, CYGNUS Matrix and VIA Matrix products carries expiry in October 2026 subject to minimum royalties, leaving the revenue runway shorter than the product pitch.

The company’s April 2026 DEF 14A proxy lists its own fiscal 2025 annual report as the primary investor source, a polite way of saying the investor landing page is not the full story. Research and development spend hit $15.2 million for the quarter-nearly half the revenue figure-while the stockholders’ equity line of $244.6 million is propped up more by the share count than by retained earnings. Cash and equivalents ended at $91.4 million, but the burn from operations suggests the runway is measured in months rather than quarters unless revenue accelerates sharply.

The company’s product pages and press site present OCMP, FiberOS and PuraForce as pillars of a regenerative pipeline, but the filings do not supply segment-level revenue splits, gross margins, or approval timelines for new indications. The official pages also do not quantify adoption metrics, reimbursement success, or hospital procurement cycles, leaving investors to infer rather than verify the commercial traction.

For a view on trading context, the company’s shares are quoted on the Nasdaq Capital Market under the symbol ORGO; however, the evidence set here is limited to SEC filings and company product pages and does not include trading volumes, valuation ranges, or analyst estimates. The renderer will display the official product images and company filings for context, but the images themselves do not prove clinical efficacy, revenue contribution, or market adoption.

The 8-K filed on 16 June 2026 and the 10-Q of 7 May 2026 disclose routine updates and did not introduce new product approvals, major customer wins, or debt financings. Regulatory catalysts therefore remain unquantified in the supplied evidence, and the company has not provided guidance in the filings reviewed. Any forward-looking statements would therefore be the company’s own projections, not externally verified targets.